Hansa Biopharma Extends Cash Runway and Advances Imlifidase Toward Key U.S. FDA Decision

Hansa Biopharma AB ( (SE:HNSA) ) has shared an update.

Hansa Biopharma reported a transitionary first quarter of 2026, with revenue falling to 34.6 MSEK from 66.3 MSEK a year earlier, reflecting a European business reorganization and rollout of structural initiatives, while European sales were primarily driven by France. Despite a wider loss for the period and ongoing cash burn, the company ended Q1 with 676.5 MSEK in cash and short-term investments, supported by a new USD 30 million convertible note from Athyrium Capital that extends its cash runway ahead of a potential U.S. launch.

Operationally, Hansa secured U.S. regulatory momentum as the FDA accepted its Biologics License Application for imlifidase and set a PDUFA action date of December 19, 2026, positioning the company for a pivotal regulatory decision in kidney transplant desensitization. The clinical pipeline advanced with plans for an oral presentation of Phase 3 ConfIdeS trial data at the American Transplant Congress, anticipated European PAES confirmatory data in Q2 2026, continued enrollment in a Phase 2 gene therapy trial in Crigler‑Najjar syndrome, and expected FDA feedback on development of next‑generation compound HNSA‑5487 for Guillain‑Barré syndrome.

In Europe, Hansa’s market access strengthened as regional reimbursement for Idefirix was authorized in Catalonia, Spain, effective April 1, 2026, enabling transplant physicians there to treat eligible patients. Together, the financing arrangements, regulatory milestones and expanding reimbursement footprint underscore Hansa’s efforts to shore up its balance sheet and clinical presence as it seeks to transition toward broader commercial adoption of its IgG‑cleaving therapies.

The most recent analyst rating on (SE:HNSA) stock is a Buy with a SEK103.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.

More about Hansa Biopharma AB

Hansa Biopharma AB is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative treatments for patients with rare immunological conditions. The Lund, Sweden-based group has operations in Europe and the U.S., built around a proprietary IgG‑cleaving enzyme platform targeting transplantation, autoimmune diseases, gene therapy and other areas with limited treatment options.

Average Trading Volume: 334,022

Technical Sentiment Signal: Strong Sell

Current Market Cap: SEK2.82B

See more data about HNSA stock on TipRanks’ Stock Analysis page.